Trial Profile

A phase IIb proof of concept trial investigating the effects of GBT-440 on oxygen saturation in patients with idiopathic pulmonary fibrosis (IPF)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2017 Status changed from planning to withdrawn prior to enrolment according to a Global Blood Therapeutics media release.
23 Oct 2017 According to a company media release, Global Blood Therapeutics has announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies, including a Phase 1 study in healthy volunteers called Basecamp and two Phase 2a studies in patients with IPF called GBT440-006 and ZEPHYR.
05 Apr 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com